Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
2(28.6%)
Phase 3
1(14.3%)
7Total
Phase 1(4)
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07257978Phase 2Not Yet Recruiting

Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome

Role: lead

NCT07257939Phase 3Not Yet Recruiting

NTI164 in Autism Spectrum Disorder

Role: lead

NCT06713447Phase 1Active Not Recruiting

NTI164 Human PK Study

Role: lead

NCT06621888Phase 1Active Not Recruiting

Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Role: lead

NCT06621043Phase 1Active Not Recruiting

Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)

Role: lead

NCT05626959Phase 2Unknown

Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder

Role: lead

NCT05516407Phase 1Unknown

Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.

Role: lead

All 7 trials loaded